SF
SRPT icon

Synovus Financial’s Sarepta Therapeutics SRPT Stock Holding History

Synovus Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-56
Closed -$9K – 1355
2020
Q2 		$9K Sell
56
-92
-62% -$12.5K ﹤0.01% 1235
2020
Q1 		$14K Buy
148
+92
+164% +$10.5K ﹤0.01% 1482
2019
Q4 		$7K Hold
56
– – ﹤0.01% 1272
2019
Q3 		$4K Hold
56
– – ﹤0.01% 1330
2019
Q2 		$9K Hold
56
– – ﹤0.01% 1144
2019
Q1 		$7K Hold
56
– – ﹤0.01% 1179
2018
Q4 		$6K Hold
56
– – ﹤0.01% 1177
2018
Q3 		$9K Buy
+56
New +$7.66K ﹤0.01% 1153
2013
Q4 		– Sell
-498
Closed -$24K – 924
2013
Q3 		$24K Hold
498
– – ﹤0.01% 630
2013
Q2 		$18K Buy
+498
New +$17.8K ﹤0.01% 652

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Synovus Financial's SRPT Position: Q3 2020 in Review

Synovus Financial sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 56 shares — an estimated $9K sold.

Synovus Financial first reported a position in SRPT in Q2 2013 and held it in 10 quarters. The position peaked at $24K in Q3 2013. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • Synovus Financial reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Synovus Financial sold 56 Sarepta Therapeutics shares in Q3 2020, an estimated $9K.
  • Synovus Financial first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 10 quarters.
  • Synovus Financial's Sarepta Therapeutics position peaked at $24K in Q3 2013.
  • 403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.